Search research articles
Contact Us
Filters
Showing results (261-270 of 333) with videos related to
Page
of 34
Sort By:
JAMA
|
January 30, 2004
Effect of breast augmentation on the accuracy of mammography and cancer characteristics
Diana L Miglioretti, Carolyn M Rutter, Berta M Geller, et al.
The Lancet. Neurology
|
November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.
The New England Journal of Medicine
|
September 30, 2016
Adjunctive Azithromycin Prophylaxis for Cesarean Delivery
Alan T N Tita, Jeff M Szychowski, Kim Boggess, et al.
Muscle & Nerve
|
May 7, 2021
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)
Amanda C Guidon, Srikanth Muppidi, Richard J Nowak, et al.
The Lancet. Neurology
|
April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
John F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Journal of the National Cancer Institute
|
October 17, 2002
Detection of ductal carcinoma in situ in women undergoing screening mammography
Virginia L Ernster, Rachel Ballard-Barbash, William E Barlow, et al.
The American Journal of the Medical Sciences
|
July 6, 2022
Satisfaction with modes of telemedicine delivery during COVID-19: A randomized, single-blind, parallel group, noninferiority trial
Maria I Danila, Dongmei Sun, Lesley E Jackson, et al.
Neurology
|
September 14, 2019
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Lana Zhovtis Ryerson, John Foley, Ih Chang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 25, 2020
Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease
Amy W Amara, Kimberly H Wood, Allen Joop, et al.
The Lancet. Neurology
|
July 21, 2023
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Nir Giladi, Roy N Alcalay, Gary Cutter, et al.
Page
of 34
Search research articles
Search
Showing results (261-270 of 333) with videos related to
Sort By:
Page
of 34
JAMA
|
January 30, 2004
Effect of breast augmentation on the accuracy of mammography and cancer characteristics
Diana L Miglioretti, Carolyn M Rutter, Berta M Geller, et al.
The Lancet. Neurology
|
November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.
The New England Journal of Medicine
|
September 30, 2016
Adjunctive Azithromycin Prophylaxis for Cesarean Delivery
Alan T N Tita, Jeff M Szychowski, Kim Boggess, et al.
Muscle & Nerve
|
May 7, 2021
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)
Amanda C Guidon, Srikanth Muppidi, Richard J Nowak, et al.
The Lancet. Neurology
|
April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
John F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Journal of the National Cancer Institute
|
October 17, 2002
Detection of ductal carcinoma in situ in women undergoing screening mammography
Virginia L Ernster, Rachel Ballard-Barbash, William E Barlow, et al.
The American Journal of the Medical Sciences
|
July 6, 2022
Satisfaction with modes of telemedicine delivery during COVID-19: A randomized, single-blind, parallel group, noninferiority trial
Maria I Danila, Dongmei Sun, Lesley E Jackson, et al.
Neurology
|
September 14, 2019
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Lana Zhovtis Ryerson, John Foley, Ih Chang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 25, 2020
Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease
Amy W Amara, Kimberly H Wood, Allen Joop, et al.
The Lancet. Neurology
|
July 21, 2023
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Nir Giladi, Roy N Alcalay, Gary Cutter, et al.
Page
of 34